产品
编 号：F041722
分子式：C21H25ClFN3O3
分子量：421.89
分子式：C21H25ClFN3O3
分子量：421.89
产品类型
规格
价格
是否有货
结构图
CAS No: 112885-41-3
产品详情
生物活性：
Mosapride citrate is an orally active gastroenterokinetic compound. Mosapride citrate is a 5HT4agonist. Mosapride citrate is a CYP inducer. Mosapride citrate has a concentration-dependent inhibitory effect on Kv4.3, and its IC50 value is 15.2 μM. Mosapride citrate can be used in the study of gastrointestinal diseases.
体内研究：
Mosapride citrate (0.3-3 mg/kg或30 mg/kg 口服) 促进大鼠胃排空，呈剂量依赖性。剂量为30 mg/kg时显著抑制大鼠胃排空。Mosapride citrate (0.25, 0.5, 0.75 mg/kg 口服) 在大鼠中可通过激活5-HT4受体来减轻非甾体抗炎药诱导的溃疡。Animal Model:NSAID-induced experimental ulcer model
Dosage:0.25, 0.5 , 0.75 mg/kg
Administration:p.o
Result:Inhibited the mucosal damage.
体外研究：
Mosapride citrate (1-100 nM) 显著增加了豚鼠结肠近端和远端收缩的平均幅度，缩短了结肠近端和远端转运时间。Mosapride citrate (869 ng/mL, 48 h) 在人肝细胞 (HMC424, 478 和 493) 中增加Cytochrome P450 (CYP1A2、2B6和3A4) 的诱导能力。
Mosapride citrate is an orally active gastroenterokinetic compound. Mosapride citrate is a 5HT4agonist. Mosapride citrate is a CYP inducer. Mosapride citrate has a concentration-dependent inhibitory effect on Kv4.3, and its IC50 value is 15.2 μM. Mosapride citrate can be used in the study of gastrointestinal diseases.
体内研究：
Mosapride citrate (0.3-3 mg/kg或30 mg/kg 口服) 促进大鼠胃排空，呈剂量依赖性。剂量为30 mg/kg时显著抑制大鼠胃排空。Mosapride citrate (0.25, 0.5, 0.75 mg/kg 口服) 在大鼠中可通过激活5-HT4受体来减轻非甾体抗炎药诱导的溃疡。Animal Model:NSAID-induced experimental ulcer model
Dosage:0.25, 0.5 , 0.75 mg/kg
Administration:p.o
Result:Inhibited the mucosal damage.
体外研究：
Mosapride citrate (1-100 nM) 显著增加了豚鼠结肠近端和远端收缩的平均幅度，缩短了结肠近端和远端转运时间。Mosapride citrate (869 ng/mL, 48 h) 在人肝细胞 (HMC424, 478 和 493) 中增加Cytochrome P450 (CYP1A2、2B6和3A4) 的诱导能力。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备